IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the instant application. The present status of each claim is indicated in parentheses following the claim number. An instruction line precedes each claim that is amended, cancelled, or added by the instant paper.

Claims **1** to **57** (CANCELLED)

Please **cancel** claims 58-74 without prejudice.

Claims **58** to **74** (CANCELLED)

Please **amend** claim 75 as follows:

75. (CURRENTLY AMENDED) A CYP1B1 substrate comprising a chemical moiety bound to a carrier framework having

the formula (Z):



wherein:

X= OH, OMe or $N(CH_3)_2$; and

n=0-3;

and;

R_1=H, C_{1-4} lower alkyl, or together with R_2 forms part of a cycloalkyl group which may be further substituted to form part of a polycyclic cycloalkyl group;

R_2=H, OMe, C_{1-4} lower alkyl, or together with R_1 and/or R_3 forms part of a cycloalkyl, polycyclic cycloalkyl, or forms part of a polycyclic aromatic group by linkage to R_4;

R_3=H, OMe, C_{1-4} lower alkyl or together with R_2 forms part of a cycloalkyl, polycyclic cycloalkyl; and

R_4=H or is fused directly to the aromatic position designated by R_2 ~~and~~ ;

F1

either:

the chemical moiety is derived from a chemical having a free amino, hydroxyl or ~~mercapto~~thiol group and which links it to the rest of the CYP1B1 substrate, such that A represents NH, NR (R=C_{1-4} lower alkyl), O or S; or

the chemical moiety is derived from a chemical having a carboxylate group, an ester linkage joining it to the rest of the CYP1B1 substrate and A being nothing~~.~~; and

the chemical moiety is selected from the group consisting of a calchone moiety, a colchicine moiety, a stilbene moiety, a daunomycin moiety, an esperimycin moiety, a nitrogen mustard moiety, a staurosporin moiety, a taxol moiety, and a fluorophore moiety.

2
~~76~~. (PREVIOUSLY PRESENTED) A CYP1B1 substrate according to claim ~~75~~ 1 wherein n=2 and R_2 and R_4 are fused forming a naphthyl group.

F

77. (PREVIOUSLY PRESENTED) A CYP1B1 substrate according to claim 75, having a formula selected from the group consisting of:

(XV):



and

(XVI):



78. (PREVIOUSLY PRESENTED) A CYP1B1 substrate according to claim 77, wherein the carrier framework is a substituted benzyl carrier framework.

Please **amend** claim 79 as follows:

79. (CURRENTLY AMENDED) A CYP1B1 substrate according to claim 78, having the general formula (Y):



wherein R_2, R_3 and X are selected from any one of the groups of:

a) R_2 = H, R_3 = H, X = OMe ~~in Formula XVIII~~;

b) R_2 = H, R_3 = OMe, X = OMe ~~in Formula XIX~~; and

c) R_2 = OMe, R_3 = H, X = OMe ~~in Formula XXII~~.

80. (PREVIOUSLY PRESENTED) A CYP1B1 substrate according to claim 78, having a formula selected from the group consisting of:

(XXIII):



(XXV):



(XXVI):



(XXVII):



and

(XXVIII):



81. (PREVIOUSLY PRESENTED) A CYP1B1 substrate according to claim 75, wherein the carrier framework is a cinnamyl carrier framework.

82. (PREVIOUSLY PRESENTED) A CYP1B1 substrate according to claim 81, having a formula of:

(XXX):



83. (PREVIOUSLY PRESENTED) A composition comprising a CYP1B1 substrate according to claim 75 and a carrier.

Please **amend** claim 84 as follows:

84. (CURRENTLY AMENDED) A method of manufacture of a medicament for the treatment of a ~~tumor,~~ tumor ~~comprising~~comprising an enzyme having aromatic hydroxylase activity comprising:

providing a CYP1B1 substrate according to claim ~~75~~ 1

and combining the CYP1B1 substrate with a

~~carrier.~~carrier,

F1

wherein the tumor is selected from the group consisting of a bladder tumor, a brain tumor, a breast tumor, a cervical tumor, a colon tumor, a connective tissue tumor, an endometrium tumor, an esophageal tumor, a kidney tumor, a lung tumor, a lymph node tumor, an ovarian tumor, a prostate tumor, a skin tumor, an intestinal tumor, a stomach tumor, a testis tumor, and a uterine tumor.

Please **amend** claim 85 as follows:

12
~~85~~. (CURRENTLY AMENDED) A method of inhibiting tumor cell growth comprising:

contacting a tumor cell with a CYP1B1 substrate

according to claim ~~75.~~ 1,

wherein the tumor cell comprises an enzyme having aromatic hydroxylase activity, and the tumor cell is selected from the group consisting of a bladder tumor

cell, a brain tumor cell, breast tumor cell, a cervical tumor cell, a colon tumor cell, a connective tissue tumor cell, an endometrium tumor cell, an esophageal tumor cell, a kidney tumor cell, a lung tumor cell, a lymph node tumor cell, an ovarian tumor cell, a prostate tumor cell, a skin tumor cell, an intestinal tumor cell, a stomach tumor cell, a testis tumor cell, and a uterine tumor cell.

Please **cancel** claim 86 without prejudice.

86. (CANCELLED)

Please **add** claim 88 as follows:

87. (NEW) A CYP1B1 substrate according to claim 81, having a formula selected from the group consisting of:

(XXXI):



and

(XXXII):



Please **add** claim 88 as follows:

88. (NEW) A CYP1B1 substrate comprising a carrier framework having the formula (Z'):



wherein:

X= OH, OMe or $N(CH_3)_2$; and

n=0-3;

and;

R_1=H, C_{1-4} lower alkyl, or together with R_2 forms part of a cycloalkyl group which may be further substituted to form part of a polycyclic cycloalkyl group;

R_2=H, OMe, C_{1-4} lower alkyl, or together with R_1 and/or R_3 forms part of a cycloalkyl, polycyclic cycloalkyl, or forms part of a polycyclic aromatic group by linkage to R_4;

R_3=H, OMe, C_{1-4} lower alkyl or together with R_2 forms part of a cycloalkyl, polycyclic cycloalkyl; and

R_4=H or is fused directly to the aromatic position designated by R_2; and

F1

A represents H, NH_2, NHR (R=C_{1-4} lower alkyl), OH or SH.